利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.025 秒)

    Methods and applications of molecular beacon imaging for infectious disease and cancer detection
    1.
    发明申请
    Methods and applications of molecular beacon imaging for infectious disease and cancer detection 审中-公开
    用于感染性疾病和癌症检测的分子信标成像的方法和应用

    公开(公告)号：US20080032282A1

    公开(公告)日：2008-02-07

    申请号：US11644400

    申请日：2006-12-22

    申请人： Augustine Lin ,  Pan-Chyr Yang ,  Cheng-Chung Chou

    发明人： Augustine Lin ,  Pan-Chyr Yang ,  Cheng-Chung Chou

    IPC分类号： C12Q1/70 ,  C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q1/701 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158

    摘要： Molecular beacon for detecting an infection and/or expression or a mutation of a disease marker for diagnostics and pharmacogenomics. The molecular beacon is capable of hybridizing a disease-related RNA or DNA of a disease marker in a specimen obtained from a living subject, thereby emitting a signal detectable without a need for signal amplification. The disease marker includes a genetic sequence specific to a pathogen including a flu virus, a cancer cell marker, and a drug resistance-related genetic mutation marker for a drug resistant cancer and infectious pathogen. To detect a disease cell, a specimen containing one or more cells is obtained from a living subject, and fixed by an organic solvent. A molecular beacon is then added to the specimen, followed by staining nuclei of the cells in the specimen. The signal is detectable with a microscope, FACS scan, ELISA plate reader, Scanner, or any combinations thereof.

    摘要翻译： 用于检测用于诊断和药物基因组学的疾病标记物的感染和/或表达或突变的分子信标。 分子信标能够与从活体受试者获得的样本中的疾病标记物的疾病相关的RNA或DNA杂交，从而发​​出可检测的信号，而不需要信号放大。 疾病标记物包括对包括流感病毒，癌细胞标志物和药物抗性相关的耐药性癌症和感染性病原体的耐药相关基因突变标记的病原体特异性的遗传序列。 为了检测疾病细胞，从活体受试者获得含有一种或多种细胞的样品，并通过有机溶剂固定。 然后将分子信标添加到样品中，随后在样品中染色细胞核。 该信号可用显微镜，FACS扫描，ELISA板读数器，扫描仪或其任何组合检测。

    Collapsin response mediator protein-1 (CRMP-1) transcriptional regulatory nucleic acid sequences
    4.
    发明授权
    Collapsin response mediator protein-1 (CRMP-1) transcriptional regulatory nucleic acid sequences 失效
    Collapsin应答介质蛋白-1（CRMP-1）转录调控核酸序列

    公开(公告)号：US07655779B2

    公开(公告)日：2010-02-02

    申请号：US11785701

    申请日：2007-04-19

    申请人： Pan-Chyr Yang ,  Tse-Ming Hong ,  Jeremy J. W. Chen ,  Cheng-Chung Wu ,  Jin-Yuan Shin ,  Yi-Jen Lee

    发明人： Pan-Chyr Yang ,  Tse-Ming Hong ,  Jeremy J. W. Chen ,  Cheng-Chung Wu ,  Jin-Yuan Shin ,  Yi-Jen Lee

    IPC分类号： C07H21/02

    CPC分类号： C12N15/85 ,  A61K48/00 ,  C12N2830/00

    摘要： This invention provides a transcription unit which is isolated from the upstream nucleic acid sequence of the collapsing response mediator protein-1 (CRMP-1) gene, an invasion-suppressor gene. The transcription unit contains a nucleic acid regulatory sequence which demonstrates promoter and/or regulatory activities (such as providing a transcription factor binding site) to enhance the expression of the CRMP-1 and/or a reporter protein. The invention also provides a DNA construct containing this transcription unit which can be transfected into a host cell. Additionally, the invention provides methods to enhance the expression of CRMP-1 and/or the reporter protein. The over-expression of CRMP-1 in a cancer cell can inhibit the metastasis of the cancer cell.

    摘要翻译： 本发明提供了从塌陷反应介质蛋白-1（CRMP-1）基因的上游核酸序列，侵袭抑制基因中分离的转录单位。 转录单元含有证明启动子和/或调节活性（例如提供转录因子结合位点）以增强CRMP-1和/或报道蛋白表达的核酸调节序列。 本发明还提供含有该转录单位的DNA构建体，其可转染入宿主细胞。 另外，本发明提供了增强CRMP-1和/或报道蛋白表达的方法。 癌细胞中CRMP-1的过度表达可以抑制癌细胞的转移。

    HLJ1 gene expression
    5.
    发明申请
    HLJ1 gene expression 审中-公开
    HLJ1基因表达

    公开(公告)号：US20060194235A1

    公开(公告)日：2006-08-31

    申请号：US11360671

    申请日：2006-02-24

    申请人： Jian-Wei Chen ,  Meng-Feng Tsai ,  Chi-Chung Wang ,  Pan-Chyr Yang

    发明人： Jian-Wei Chen ,  Meng-Feng Tsai ,  Chi-Chung Wang ,  Pan-Chyr Yang

    IPC分类号： C12Q1/68 ,  G01N33/574 ,  C07H21/04 ,  C07K16/30 ,  C07K14/82

    CPC分类号： C12Q1/6886 ,  C07K14/47 ,  C07K16/18 ,  C12Q2600/118 ,  C12Q2600/136 ,  G01N33/57423 ,  G01N33/57496 ,  G01N2500/00

    摘要： The human HLJ1 tumor suppressor gene is herein defined as regulated by promoter, enhancer, and silencer regions. HLJ1 promoter activity and gene expression are inversely correlated with metastatic ability. HLJ1 is highly expressed, and inducible, in cells with low metastatic ability and expressed to a lesser extent in highly metastatic cells. HLJ1 gene expression suppressed the growth of human lung adenocarcinoma cells in vitro, and inhibited tumor growth in vivo. It also impeded the motility of human adenocarcinoma cells and reduced the anchorage-independent growth capacity and invasiveness of metastatic lung adenocarcinoma cells. The degree to which human lung adenocarcinoma patients express HLJ1 predicts their survival prognosis and their probability of relapse.

    摘要翻译： 本文定义的人HLJ1肿瘤抑制基因被启动子，增强子和消音区限制。 HLJ1启动子活性和基因表达与转移能力呈负相关。 HLJ1在具有低转移能力的细胞中高度表达并且可诱导，并且在高度转移的细胞中表达较少程度。 HLJ1基因表达体外抑制人肺腺癌细胞生长，体内抑制肿瘤生长。 它也阻碍了人腺癌细胞的运动，降低了锚定依赖性的生长能力和转移性肺腺癌细胞的侵袭能力。 人肺腺癌患者表达HLJ1的程度预测其生存预后及其复发概率。

    Collapsin response mediator protein-1 (CRMP-1) transcriptional regulatory nucleic acid sequences
    7.
    发明授权
    Collapsin response mediator protein-1 (CRMP-1) transcriptional regulatory nucleic acid sequences 失效
    Collapsin应答介质蛋白-1（CRMP-1）转录调控核酸序列

    公开(公告)号：US07211660B2

    公开(公告)日：2007-05-01

    申请号：US11051328

    申请日：2005-02-07

    申请人： Pan-Chyr Yang ,  Tse-Ming Hong ,  Jeremy J. W. Chen ,  Cheng-Chung Wu ,  Jin-Yuan Shin ,  Yi-Jen Lee

    发明人： Pan-Chyr Yang ,  Tse-Ming Hong ,  Jeremy J. W. Chen ,  Cheng-Chung Wu ,  Jin-Yuan Shin ,  Yi-Jen Lee

    IPC分类号： C07H21/04 ,  C12P21/04 ,  C12N15/86

    CPC分类号： C12N15/85 ,  A61K48/00 ,  C12N2830/00

    摘要： This invention provides a transcription unit which is isolated from the upstream nucleic acid sequence of the collapsing response mediator protein-1 (CRMP-1) gene, an invasion-suppressor gene. The transcription unit contains a nucleic acid regulatory sequence which demonstrates promoter and/or regulatory activities (such as providing a transcription factor binding site) to enhance the expression of the CRMP-1 and/or a reporter protein. The invention also provides a DNA construct containing this transcription unit which can be transfected into a host cell. Additionally, the invention provides methods to enhance the expression of CRMP-1 and/or the reporter protein. The over-expression of CRMP-1 in a cancer cell can inhibit the metastasis of the cancer cell.

    摘要翻译： 本发明提供了从塌陷反应介质蛋白-1（CRMP-1）基因的上游核酸序列，侵袭抑制基因中分离的转录单位。 转录单元含有证明启动子和/或调节活性（例如提供转录因子结合位点）以增强CRMP-1和/或报道蛋白表达的核酸调节序列。 本发明还提供含有该转录单位的DNA构建体，其可转染入宿主细胞。 另外，本发明提供了增强CRMP-1和/或报道蛋白表达的方法。 癌细胞中CRMP-1的过度表达可以抑制癌细胞的转移。

    PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER USING PHENOTHIAZINE
    8.
    发明申请
    PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER USING PHENOTHIAZINE 审中-公开
    用于治疗癌症的药物组合物使用苯并噻唑

    公开(公告)号：US20160120876A1

    公开(公告)日：2016-05-05

    申请号：US14841727

    申请日：2015-09-01

    申请人： Chi-Ying Huang ,  Jane Hsiao ,  Pan-Chyr Yang ,  Meng-Hua Lee

    发明人： Chi-Ying Huang ,  Jane Hsiao ,  Pan-Chyr Yang ,  Meng-Hua Lee

    IPC分类号： A61K31/5415 ,  A61K33/24 ,  A61K31/5377

    CPC分类号： A61K31/5415 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/549 ,  A61K31/555 ,  A61K31/7068 ,  A61K33/24 ,  A61K2300/00

    摘要： The present invention relates to use of antipsychotic phenothiazine derivative for treatment of cancer. The invention also provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating a cancer, and/or preventing or delaying cancer recurrence based on trifluoperazine. The invention further provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating cancer based on thioridazine and its enantiomers. Additionally, the invention provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating KRAS mutant NSCLC comprising thioridazine.

    摘要翻译： 本发明涉及抗精神病药吩噻嗪衍生物用于治疗癌症的用途。 本发明还提供了用于制备药物，药物组合物和治疗癌症的方法，和/或预防或延迟基于三氟拉嗪的癌症复发的用途。 本发明还提供了制备用于治疗基于硫利达嗪及其对映异构体的癌症的药物，药物组合物和方法的用途。 另外，本发明提供了用于制备药物，药物组合物和用于治疗包含硫利达嗪的KRAS突变NSCLC的方法的用途。